Regulation
FDA Peptide Status Tracker
Where every peptide on this site stands with the FDA, the pharmacy compounding lists, the WADA list and the DEA. We read the records ourselves and put a date on every row.
- 6 of 26 are FDA approved
- 6 FDA approved
- 20 not approved
- 11 of 26 are banned in sport by WADA
- 11 banned by WADA
- 15 not banned or unclear
- 1 of 26 is on FDA's drug shortage list
- 1 in shortage
- 25 not in shortage
Each square is one of the 26 peptides on this site. Select a square to open that peptide's page.
Can a pharmacy make it?
Most peptides sold online have no FDA approval, so the question that matters is whether a compounding pharmacy may make them. Under section 503A of the drug law, every peptide here lands in one of four places.
13 of 26 may be made by a compounding pharmacy today. 13 may not.
Allowed 6 peptides
It is an ingredient in an FDA-approved drug, so a pharmacy may compound it with a prescription. Copies of a drug already on the market are still limited.
Allowed for now 7 peptides
It is on FDA's Category 1 list or HHS's October 2026 interim peptide policy, which let pharmacies compound it, under conditions, while FDA reviews it. Neither is FDA approval.
Flagged for safety 2 peptides
FDA put it in Category 2, the list for substances with significant safety concerns.
Not allowed 11 peptides
It is on no list that allows it. Most were nominated and then withdrawn; others were never nominated, lacked support, or are biologics.
Every peptide, row by row
| Peptide | FDA approvedSold as a prescription drug? | 503A compoundingCan a local pharmacy make it? | 503B bulks listCan a large outsourcing pharmacy make it? | Drug shortageOn FDA's shortage list? | WADABanned in sport? | DEAA controlled substance? | Last verifiedWhen we last checked | SourcesThe records we read |
|---|---|---|---|---|---|---|---|---|
| AOD-9604FDA advisers voted 12 to 0 against adding it to the 503A bulks list on Dec 4, 2024. | No | Nomination withdrawn or removed | Not nominated | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8] | |
| BPC-157Since Oct 28, 2026 it is covered by HHS's interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | No | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval) | Not nominated | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8][9][10][11] | |
| Bremelanotide (PT-141)Approved June 21, 2019 as Vyleesi (NDA 210557), with no record in the FDA drug shortage database. FDA treats products sold online as PT-141 as unapproved new drugs. | Yes (2019)Vyleesi | Component of an FDA-approved drug | Not nominated | Not on the shortage list | No | Not scheduled | [1][2][3][4][5][6][7][8][9] | |
| CagrilintideInvestigational, with no FDA-approved product and no FDA shortage record. FDA states it cannot be used in compounding under federal law (page current Oct 1, 2026). | No | Not nominated | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7][8] | |
| CJC-1295FDA advisers voted against adding it to the 503A bulks list on Dec 4, 2024. | No | Nomination withdrawn or removed | Not nominated | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8][9] | |
| EpitalonSince Oct 28, 2026 it is covered by HHS's interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | No | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval) | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| GHK-CuNon-injectable GHK-Cu is back in 503A Category 1 (list updated May 14, 2026), with an advisory committee review planned before the end of February 2027. | No | Category 1 (may be compounded while FDA evaluates) | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7][8][9] | |
| GHRP-2 and GHRP-6Both are in 503A Category 3, and both are in 503B Category 2 (GHRP-2 only for injectable and nasal routes). | No | Category 3 (nominated without enough support) | Category 2 (significant safety concerns) | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7] | |
| IpamorelinFDA advisers voted against adding it to the 503A bulks list on Oct 29, 2024, and it is in 503B Category 2. | No | Nomination withdrawn or removed | Category 2 (significant safety concerns) | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| KisspeptinKisspeptin-10 has been in 503A Category 2 (significant safety risks) since Sept 29, 2023. | No | Category 2 (significant safety concerns) | Not nominated | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8] | |
| KPVSince Oct 28, 2026 it is covered by HHS's interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | No | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval) | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7][8][9][10][11] | |
| LiraglutideFirst approved Jan 25, 2010 as Victoza. Liraglutide injection is still listed as a current FDA shortage (first posted July 18, 2023), and FDA proposed keeping it off the 503B bulks list (May 1, 2026). | Yes (2010)Victoza, Saxenda, Liraglutide injection, generic | Component of an FDA-approved drug | FDA proposed not to include | Currently in shortage | No | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| LL-37FDA lists cathelicidin LL-37 as a withdrawn former 503A Category 2 substance. | No | Nomination withdrawn or removed | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7] | |
| Melanotan IIIts 503A Category 2 nomination was withdrawn, and an FDA advisory committee review is planned before the end of February 2027. | No | Nomination withdrawn or removed | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7][8][9] | |
| MK-677 (Ibutamoren)Not a peptideIbutamoren mesylate is in Category 2 (significant safety risks) for both 503A and 503B compounding. | No | Category 2 (significant safety concerns) | Category 2 (significant safety concerns) | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| MOTS-cSince Oct 28, 2026 it is covered by HHS's interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | No | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval) | Not nominated | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| Oxytocin1980 is the earliest oxytocin approval shown in Drugs@FDA (Syntocinon, NDA 018245, Apr 17, 1980), recorded as a new formulation or new manufacturer, so older approvals may not be listed there. No record in the FDA drug shortage database. | Yes (1980)Pitocin, Oxytocin Injection, USP generic | Component of an FDA-approved drug | Under evaluation (Category 1) | Not on the shortage list | No | Not scheduled | [1][2][3][4][5][6][7][8][9] | |
| RetatrutideInvestigational, with no FDA-approved product and no FDA shortage record. FDA states it cannot be used in compounding under federal law (page current Oct 1, 2026). | No | Not nominated | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7] | |
| SelankIts 503A nomination was withdrawn, and it was not on the July 2026 advisory committee agenda. | No | Nomination withdrawn or removed | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7] | |
| SemaglutideFirst approved Dec 5, 2017 as Ozempic. FDA declared the injection shortage resolved Feb 21, 2025, and proposed keeping semaglutide off the 503B bulks list (May 1, 2026). | Yes (2017)Ozempic injection, Wegovy injection and tablets, Rybelsus and Ozempic tablets | Component of an FDA-approved drug | FDA proposed not to include | Shortage resolved | No | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| SemaxSince Oct 28, 2026 it is covered by HHS's interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | No | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval) | Not nominated | Not on the shortage list | Unclear | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| SermorelinFirst approved Dec 28, 1990 as Geref (NDA 019863); Geref was later discontinued and its approvals withdrawn, and FDA determined in 2013 that it was not withdrawn for safety or effectiveness reasons. No record in the FDA drug shortage database. | No (1990) | Component of an FDA-approved drug | Under evaluation (Category 1) | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8] | |
| TB-500 and Thymosin Beta-4Since Oct 28, 2026 it is covered by HHS's interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | No | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval) | Not nominated | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7][8][9][10][11] | |
| TesamorelinFirst approved Nov 10, 2010 as Egrifta, and regulated as a biologic since March 23, 2020, which FDA says makes it ineligible for 503A and 503B compounding. No record in the FDA drug shortage database. | Yes (2010)Egrifta WR, Egrifta SV | Biologic, not eligible for 503A compounding | Biologic, not eligible for 503B compounding | Not on the shortage list | Yes | Not scheduled | [1][2][3][4][5][6][7] | |
| Thymosin Alpha-1FDA advisers voted 17 to 4 against adding it to the 503A bulks list on Dec 4, 2024. | No | Nomination withdrawn or removed | Category 3 (nominated without enough support) | Not on the shortage list | No | Not scheduled | [1][2][3][4][5][6][7][8][9][10] | |
| TirzepatideFirst approved May 13, 2022 as Mounjaro. FDA declared the injection shortage resolved Dec 19, 2024, and proposed keeping tirzepatide off the 503B bulks list (May 1, 2026). | Yes (2022)Mounjaro, Zepbound | Component of an FDA-approved drug | FDA proposed not to include | Shortage resolved | No | Not scheduled | [1][2][3][4][5][6][7][8][9][10] |
How we check
We use primary records only: FDA's 503A and 503B bulk substance lists and docket FDA-2018-N-3240, the FDA drug shortage database, Drugs@FDA, DailyMed, the current WADA Prohibited List and the DEA's list of controlled substances. The numbers in each row's Sources cell are the records we read for it.
The whole table is rechecked every week. A row's date is the last time we confirmed it against those records. When a status changes, we update the row and the peptide's page, and post a dated note in News.
Under WADA, "Unclear" means the substance is not named on the list, and WADA has not said whether its catch-all class for unapproved substances covers it.
This is legal and regulatory status only. It does not say whether any product is safe or effective, and it is not medical advice. Dosing is set by a licensed provider.
Spot a mistake? Email info@livingplusrx.com with the row and the record that shows the right answer. Fixes go in the corrections log.
Writing about peptide rules? This table is free to cite and download. Reporters can contact us here.